238 related articles for article (PubMed ID: 27175597)
21. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
22. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
23. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.
Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH
Cancer Res; 2006 Feb; 66(3):1712-20. PubMed ID: 16452231
[TBL] [Abstract][Full Text] [Related]
24. A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice.
Hu J; Yang T; Xu H; Hu M; Wen H; Jiang H
Int Urol Nephrol; 2016 Oct; 48(10):1649-55. PubMed ID: 27282153
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
26. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice.
Raina K; Singh RP; Agarwal R; Agarwal C
Cancer Res; 2007 Jun; 67(12):5976-82. PubMed ID: 17575168
[TBL] [Abstract][Full Text] [Related]
27. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
Leman ES; Madigan MC; Brünagel G; Takaha N; Coffey DS; Getzenberg RH
J Cell Biochem; 2003 Feb; 88(3):599-608. PubMed ID: 12532335
[TBL] [Abstract][Full Text] [Related]
28. Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model.
Zhang J; Ahn KS; Kim C; Shanmugam MK; Siveen KS; Arfuso F; Samym RP; Deivasigamanim A; Lim LH; Wang L; Goh BC; Kumar AP; Hui KM; Sethi G
Antioxid Redox Signal; 2016 Apr; 24(11):575-89. PubMed ID: 26649526
[TBL] [Abstract][Full Text] [Related]
29. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells.
Han JH; Park SY; Kim JB; Cho SD; Kim B; Kim BY; Kang MJ; Kim DJ; Park JH; Park JH
Am J Reprod Immunol; 2013 Oct; 70(4):317-26. PubMed ID: 23790156
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
31. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
32. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
33. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
34. Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model.
Lawrence MD; Ormsby RJ; Blyth BJ; Bezak E; England G; Newman MR; Tilley WD; Sykes PJ
Radiat Res; 2013 Oct; 180(4):376-88. PubMed ID: 23971516
[TBL] [Abstract][Full Text] [Related]
35. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
[TBL] [Abstract][Full Text] [Related]
37. Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet.
Xu H; Hu MB; Bai PD; Zhu WH; Liu SH; Hou JY; Xiong ZQ; Ding Q; Jiang HW
Biomed Res Int; 2015; 2015():249741. PubMed ID: 25722971
[TBL] [Abstract][Full Text] [Related]
38. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
Yang D; Holt GE; Velders MP; Kwon ED; Kast WM
Cancer Res; 2001 Aug; 61(15):5857-60. PubMed ID: 11479226
[TBL] [Abstract][Full Text] [Related]
39. A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments.
Lardizabal J; Ding J; Delwar Z; Rennie PS; Jia W
Prostate; 2018 May; 78(6):457-468. PubMed ID: 29450905
[TBL] [Abstract][Full Text] [Related]
40. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
